Anavex Life SciencesLTS:0HFR -4.85%32 EV-to-FCF is -2.93 as of Jul. 11, 2026. GuruFocus rates LTS:0HFR with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 330 Biotechnology companies, Anavex Life Sciences ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anavex Life Sciences's Enterprise Value is $99.93 Mil.
Anavex Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-34.08 Mil. Therefore, Anavex Life Sciences's EV-to-FCF for today is -2.93.
The historical rank and industry rank for Anavex Life Sciences's EV-to-FCF or its related term are showing as below:
LTS:0HFR'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.93 Med: 0 Max: 0
Current: -2.93
LTS:0HFR's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs LTS:0HFR: -2.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anavex Life Sciences (LTS:0HFR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anavex Life Sciences's PE Ratio (TTM) for today is calculated as:
Anavex Life Sciences's share price for today is $2.55.
Anavex Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anavex Life Sciences EV-to-FCF Related Terms
Anavex Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Anavex Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HFR vs SLGL, FATE, FHTX: EV-to-FCF Comparison
For the Biotechnology subindustry, Anavex Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's EV-to-FCF falls into.
Anavex Life Sciences's current Enterprise Value is $99.93 Mil.
Anavex Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (LTS:0HFR) has a EV-to-FCF of -2.93 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anavex Life Sciences and its competitors. According to the industry distribution chart, Anavex Life Sciences ranks #999999 out of 330 companies in the Biotechnology industry.
Is Anavex Life Sciences' EV-to-FCF too high?
Anavex Life Sciences' current EV-to-FCF is -2.93. Based on the distribution chart, Anavex Life Sciences ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anavex Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' EV-to-FCF compare to SLGL and FATE?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #999999 out of 330 companies for EV-to-FCF. This places Anavex Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Anavex Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anavex Life Sciences's current EV-to-FCF is -2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (LTS:0HFR) has a current EV-to-FCF of -2.93. The current EV-to-FCF is -2.93. Anavex Life Sciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Anavex Life Sciences (LTS:0HFR), the current EV-to-FCF is -2.93 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
32GF Score
Get the complete analysis for LTS:0HFR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HFR has been successfully added to your 
